Here, we present the first study on the effects of compounds that interfere with calcium (Ca 2ϩ ) handling by the endoplasmic reticulum (ER) and mitochondria on amperometrically measured quantal catecholamine release from single adrenal chromaffin cells of control and spontaneously hypertensive rats (SHRs). Acetylcholine (ACh) or K ϩ pulses triggered spike bursts of secretion by Ca 2ϩ entry through Ca 2ϩ channels. ER Ca 2ϩ release triggered by a mixture of caffeine, ryanodine, and thapsigargin (CRT) or carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) (a mitochondrial protonophore) also caused bursts of secretory spikes. The spike bursts generated by ACh, K ϩ , CRT, and FCCP were 3 to 4 times longer in SHRs compared with control cells; furthermore, the individual spikes were faster and had 3-fold greater quantal size. In additional experiments, a 90-s treatment was made with CRT or FCCP to block Ca 2ϩ handling by the ER and mitochondria. In these conditions, the integrated spike burst responses elicited by ACh and K ϩ were potentiated 2-to 3-fold in control and SHR cells. This suggests that variations in Ca 2ϩ entry and its subsequent redistribution into the ER and mitochondria are not responsible for the greater secretion seen in SHRs compared with control cells; rather, such differences seem to be due to greater quantal content of spike bursts and to greater quantal size of individual amperometric events.The differential release into the circulation of the catecholamines norepinephrine and epinephrine from the adrenal medullary gland, either in basal or stressful conditions, is tightly regulated by various central (Folkow and Von Euler, 1954) and peripheral splanchnic nerve stimulation (Mirkin, 1961;Klevans and Gebber, 1970) patterns. Alteration of the activity of the sympathoadrenal medullary axis and of the rate of catecholamine release has been implicated in the pathogenesis of essential hypertension, as proven by three facts: 1) the classic effects of drugs interfering with this axis, used to treat hypertensive patients such as blockers of ␣-and -adrenergic receptors, reserpine, ␣-methyldopa, ganglionic blocking agents, guanethidine, or angiotensin II receptor blockers (Westfall and Westfall, 2007); 2) plasma levels of norepinephrine and epinephrine are augmented in spontaneously hypertensive rats (SHRs) (Iriuchijima, 1973;Grobecker et al., 1975;Pak, 1981), as happens to be the case in humans suffering essential hypertension (Goldstein, 1983); and 3) hypertensive patients have elevated sympathetic nerve activity, as revealed with microneurography (Anderson et al., 1989).Numerous studies support the notion that pre-and postsynaptic sympathetic dysfunctions are involved in the pathophysiology of human or animal primary hypertension (Tsuda and Masuyama, 1991;de Champlain et al., 1999). Studies on presynaptic mechanisms have been performed in SHRs, showing that norepinephrine release is increased in different tissues rich in sympathetic nerve endings (Donohue